文献速递腹部介入CTMRDSA

METAL评分用于早期分层接受TACE联合免疫治疗的肝细胞癌患者的影像学缓解与生存

The METAL Score for Early Stratification of Radiological Response and Survival in Hepatocellular Carcinoma Treated with TACE and Immunotherapy Combinations.
PubMed 文献 · Acad Radiol · 2025-11-04

这项多中心回顾性研究基于转移负荷、甲胎蛋白和白蛋白-胆红素分级构建了METAL评分,在378例接受TACE联合靶向及免疫治疗的不可切除肝细胞癌患者中开发,并在148例外部队列中验证。低、中、高危组中位总生存期在开发队列分别为30.8、25.2和11.6个月,验证队列分别为34.6、23.0和14.8个月,确认客观缓解率随风险分层升高而递减,且METAL低评分组接受三联治疗的总生存期和客观缓解率优于单独系统治疗。

要点

  • METAL评分由转移负荷、甲胎蛋白和白蛋白-胆红素分级三项变量构成
  • 低、中、高危组中位OS在开发队列为30.8、25.2、11.6个月,验证队列为34.6、23.0、14.8个月
  • METAL低评分组三联治疗较系统治疗单药中位OS更长且ORR更高

核心结论

  • METAL评分可早期识别最可能从三联治疗中获益的不可切除肝细胞癌理想候选者。

研究设计与样本

  • 多中心回顾性研究,开发队列n=378,外部队列n=148,另在n=232例未接受TACE的系统治疗队列中评估;纳入2018年12月至2023年8月13家三级医院接受一线三联治疗的不可切除肝细胞癌患者。

诊断标准与关键数值

  • METAL评分基于转移负荷、甲胎蛋白和白蛋白-胆红素分级三项变量构建;开发队列C-index为0.70、验证队列C-index为0.70;开发队列整合Brier评分为0.140、验证队列为0.122;开发队列低、中、高危组中位OS分别为30.8、25.2、11.6个月(均p<0.001);验证队列分别为34.6、23.0、14.8个月(均p<0.001)。

临床应用与阅片要点

  • METAL低评分组接受三联治疗较系统治疗单药的中位OS为32.6 vs. 23.8个月(p=0.034),确认ORR为77.2% vs. 48.1%(p<0.001);该评分在开发队列和验证队列中区分度均优于现有TACE相关或免疫治疗相关模型。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To develop and validate a prognostic stratification tool for patients with unresectable hepatocellular carcinoma (uHCC) receiving transarterial chemoembolization (TACE) combined with targeted and immunotherapy (triple therapy).

MATERIALS AND METHODS: This multicenter retrospective study included uHCC patients treated with first-line triple therapy at 13 tertiary hospitals from December 2018 to August 2023. A prognostic score was developed (n=378) based on multivariate Cox regression and validated in an external cohort (n=148). Radiological response and overall survival (OS) were assessed across different risk strata. Score performance was compared to existing prognostic models and further evaluated in a separate cohort receiving systemic therapy without TACE (n=232).

RESULTS: A three-variable score (METAL) integrating metastatic burden, alpha-fetoprotein, and albumin-bilirubin grade was developed. Median OS for low-, intermediate-, and high-risk groups was 30.8, 25.2, and 11.6 months in the derivation cohort, and 34.6, 23.0, and 14.8 months in the external validation cohort, respectively (all p<0.001). In both cohorts, confirmed objective response rates (ORR) also declined progressively across risk strata (all p<0.001). The current score was superior to existing TACE- or immunotherapy-related models, with higher discrimination and lower prediction error (C-index, 0.70 and 0.70; integrated Brier score, 0.140 and 0.122 in the derivation and validation cohorts, respectively). The METAL-low score successfully identified a subgroup achieving significantly longer OS (32.6 vs. 23.8 months; p=0.034) and higher ORR (77.2% vs. 48.1%; p<0.001) with triple therapy compared to systemic therapy alone.

CONCLUSION: The proposed METAL score enables early identification of ideal uHCC candidates most likely to benefit from triple therapy.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Chen Q, Lin LW, Jin ZC, et al. The METAL Score for Early Stratification of Radiological Response and Survival in Hepatocellular Carcinoma Treated with TACE and Immunotherapy Combinations. Acad Radiol. 2025. PMID: 41188158. doi:10.1016/j.acra.2025.10.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。